Serotonin Control of Impulsivity in Tourette Disorder

Launched by HOSPICES CIVILS DE LYON · Jul 4, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Serotonin Control of Impulsivity in Tourette Disorder," is investigating how certain brain receptors, specifically the 5-HT2A serotonin receptors, may affect impulsive behaviors in adults with Tourette Disorder (TD). Tourette Disorder is a condition that causes involuntary movements and sounds, known as tics, and is often linked to issues like impulsivity and anxiety. The researchers want to understand how these receptors work in the brain and how they might be involved in managing the emotional and cognitive challenges that come with TD. To do this, they will use advanced imaging techniques to look at brain activity and receptor binding in participants.

Eligible participants for this study are adults aged 18 to 65 who have a diagnosis of Tourette Disorder and are already scheduled to receive treatment with a medication called aripiprazole. Participants must be able to give their consent to join the study and should not have serious uncontrolled psychiatric conditions or other health issues that might interfere with the research. Those who take certain drugs that affect serotonin or have medical devices that could be impacted by imaging scans are also excluded. If you join the study, you can expect to undergo brain imaging procedures that are safe and non-invasive, which will help the researchers learn more about the role of serotonin in Tourette Disorder.

Gender

ALL

Eligibility criteria

• * Inclusion Criteria \* :
• • Male or Female
• • Diagnosed with a Tourette Disorder following the DSM-5
• • Age between 18-65 years
• • Member of a social security scheme in France
• • Freely-given informed consent to participate to this study (written form)
• • With a current treatment by aripiprazole already scheduled
• • With Tics compatible with TEP/fMRI exams
• • Having (for women only) effective contraception throughout participation in the study.
• Exclusion Criteria \* :
• • Male or Female
• • A serious not controlled psychiatric comorbidity
• • A serious, evolving or debilitating pathology with a potential influence on the study
• • Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
• • Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
• • Women breastfeeding
• • Protected or restricted person (administratively or in judicial terms)
• • Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
• • Do not speak french